Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Recruiting

Phase 3

Guselkumab vs. GolimumabGuselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Sponsor:

University of Pennsylvania

Code:

NCT05669833

Conditions

Psoriatic Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Guselkumab

Golimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-17. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2025-10-09.